A register study explored worldwide data on MACEs and venous thromboembolism associated with JAK inhibitors compared to anti-TNF agents in RA.
Prof. Dr. Reinhard Renneberg uses his own DNA as an example to show which migratory routes his earliest ancestors took.
A post-hoc trial analysis revealed nintedanib treatment benefit in patients with 4 characteristics associated with a fast decline in lung function.
A large register study in Denmark detected a substantially higher mortality risk for patients with rheumatoid arthritis (RA) who had comorbid depression.
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial.
Cohort study data detected factors linked to a risk amplification for dementia development in patients with rheumatoid arthritis.
During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares.
Once-daily therapy with upadacitinib led to an ASAS40 response in 45% of patients with active nr-axSpA at week 14 in the SELECT-AXIS-2 trial.
esanum talks with Prof. Brunetti about AI in medicine, its ethical implications and physicians' approach to this tech revolution.
Trial results show equal DA-EPOCH-R efficacy to CODOX-M/R-IVAX as first-line treatment in patients, but less toxicity.
New technologies have transformed haematology. Gene-editing and molecular agents become available to patients within shorter timeframes.
A Chinese meta-analysis of studies on the treatment of scleroderma has investigated whether ACE inhibitors can be used to prevent renal crisis.
esanum talks with Prof. Bonini about her research projects, her EHA board role and the prospects for young hematologists who wish to engage in research.
Leniolisib is safe, increases naïve B cells, decreases lymphadenopathy and spleen size, and improves cytopenia in APDS/PASLI.
Early ASCT in lenalidomide / bortezomib / dexamethasone therapy followed by lenalidomide maintenance, significantly improves PFS for newly diagnosed MM
Exa-cel gene-editing therapy is associated with increase in foetal and total Hb in transfusion-dependent β-thalassemia or severe sickle cell disease patients.
Phase-3 trial shows improved PFS with venetoclax/obinutuzumab/ibrutinib therapy in fit, untreated patients with chronic lymphocytic leukaemia.
A new platform connects the spheres of medical care and health innovation. It allows caregivers to find assignments with innovation actors, including companies.
CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in AML patients with adverse cytogenetics.
Continued treatment with luspatercept, for up to 3 years, allowed more patients to experience a reduction in red blood cell transfusion burden.